Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients - PACE-CME

Residual inflammatory risk is major driver of CV events and mortality in statintreated patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Imaging study with PCSK9 inhibitor in patients with stable CAD
Imaging study with PCSK9 inhibitor in patients with stable CAD
ACC.23
Imaging study with PCSK9 inhibitor in patients with stable CAD
- Annapoorna Kini, MD
Do personalized reminders to clinicians result in higher use of high-intensity statins?
Do personalized reminders to clinicians result in higher use of high-intensity statins?
ACC.23
Do personalized reminders to clinicians result in higher use of high-intensity statins?
- Prof. Salim Virani, MD, PhD
Well-designed EHR tools can improve prescribing of MRA in HFrEF
Well-designed EHR tools can improve prescribing of MRA in HFrEF
ACC.23
Well-designed EHR tools can improve prescribing of MRA in HFrEF
- Amrita Mukhopadhyay, MD
Interesting developments in the field of PCSK9 inhibition
Interesting developments in the field of PCSK9 inhibition
ACC.23
Interesting developments in the field of PCSK9 inhibition
- Deepak Bhatt, MD